4/A: Arvinas CEO RSU Grant Corrected in Amended Filing

An amended SEC filing corrects the number of restricted stock units granted to Arvinas President and CEO Randy Teel, reducing the reported amount.

Summary

• Randy Teel, President and CEO of Arvinas, Inc., received a grant of Restricted Stock Units (RSUs) on February 26, 2026.
• An amendment to the Form 4 filing was submitted on March 12, 2026, to correct a clerical error in the original filing dated March 2, 2026.
• The original filing incorrectly reported 147,791 RSUs awarded; the corrected number of RSUs is 147,179.
• This correction also adjusted the total amount of securities beneficially owned by Mr. Teel following the transaction.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration.
• The RSUs will vest over four years, with one-quarter vesting on February 12, 2027, February 12, 2028, February 12, 2029, and February 12, 2030, subject to Mr. Teel's continued service with the Issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While a clerical error is a minor administrative oversight, the prompt correction demonstrates transparency. The underlying RSU grant is a standard positive for executive retention.

Positives

• The company demonstrated transparency by promptly filing an amendment to correct a clerical error.
• The RSU grant, despite the minor correction, aligns management's long-term interests with shareholder value through a multi-year vesting schedule.

Negatives

• A clerical error in the initial filing indicates a minor administrative oversight in reporting insider transactions.
• The corrected number of RSUs granted was slightly lower than initially reported, a reduction of 612 units (from 147,791 to 147,179).

Future Outlook

The RSUs granted to Randy Teel will vest over a four-year period, with specific vesting dates extending through February 12, 2030, contingent on his continued service. This indicates a long-term retention strategy for key management.

Management Comments

• "This amendment is being filed to correct an inadvertent clerical error in reporting the number of RSUs awarded on February 26, 2026."
• "The correct number of RSUs awarded was 147,179, not 147,791, as was originally reported on the Form 4 filed on March 2, 2026."

Industry Context

StockSavvy.ai notes that equity compensation, particularly through Restricted Stock Units with multi-year vesting schedules, is a standard practice in the biotechnology and pharmaceutical industries to incentivize and retain executive talent. This aligns management's long-term interests with shareholder value creation, a common strategy among peers like Vertex Pharmaceuticals or Regeneron.

Comparison to Industry Standards

• The use of RSUs with a four-year vesting schedule is a common and competitive practice for executive compensation in the biotech sector, comparable to plans seen at companies such as Moderna or BioNTech, which also utilize long-term equity incentives to retain key personnel and align their performance with company growth.
• The grant of 147,179 RSUs to a President and CEO is within the typical range for a company of Arvinas's size and stage, similar to grants observed at mid-cap biotech firms.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides clarity on executive equity ownership, correcting a minor discrepancy. The long-term vesting of RSUs aligns executive incentives with shareholder value.
• Employees: The RSU grant and vesting schedule demonstrate the company's commitment to retaining key leadership.

Next Steps

• Randy Teel's RSUs will vest in four equal annual installments on February 12, 2027, February 12, 2028, February 12, 2029, and February 12, 2030, subject to continued service.

Key Dates

Recommendation

This filing is an administrative correction of an insider transaction and does not contain information that would fundamentally alter the investment thesis for Arvinas. The RSU grant itself is a standard executive compensation practice. Therefore, a "hold" recommendation is appropriate as this filing provides no new material information to change an existing position.

Keywords

Arvinas, ARVN, Randy Teel, Restricted Stock Units, RSU, SEC Form 4/A, Insider Transaction, Equity Compensation, Stock Incentive Plan, Corporate Governance